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DiagnosticsIdentiﬁcation of biomarkers for positive and negative predictors of response to cancer therapeutics can help
direct clinical strategies. However, challenges with tissue availability and costs are signiﬁcant limiting factors
for diagnostic assays. To address these challenges, we have customized a high-throughput single nucleotide
polymorphism genotyping assay with the objective of simultaneously surveying known somatic mutations
and copy number alterations for translational studies in cancer. As constructed, this assay can interrogate 376
known somatic mutations and quantify copy number alterations of genes commonly implicated in
tumorigenesis or progression. Validation of this assay on a panel of 321 cell lines demonstrates sensitivity
to accurately detect mutations, robust accuracy in the presence of inﬁltrating normal tissue, and the ability to
detect both DNA copy number ampliﬁcations and deletions. This technology, with its high sensitivity, small
DNA requirements, and low costs is an attractive platform for biomarker exploration in cancer..
l rights reserved.© 2011 Elsevier Inc. All rights reserved.1. Introduction
A more complete list of genes involved with tumorigenesis and
cancer progression has emerged as a result of ongoing high
throughput mutation screening. Sequence mutations have been
crucial in identifying novel targets for cancer therapeutics as well as
predicting response proﬁles to cancer treatments. For example,
mutations of ALK and EGFR correlate with response to PH-02341066
[1] and geﬁtinib [2] while KRAS mutations are reported to be
associated with resistance to EGFR tyrosine kinase inhibitors [3].
Unfortunately their use in clinical trials is confounded by the high cost
of screening and limitations on patient tissue availability. Also, while
some evidence suggests that key mutations can preferentially co-
occur in the same tumor (e.g. PIK3CA and KRAS in colon cancer) [4]
few studies have screened the same tumor for multiple mutations.
In order to increase the clinical feasibility of high throughput
somatic mutation screening on individual tumors, we have developed
a custom genotyping assay based on the Illumina Golden Gate
platform [5] (Illumina, Inc., San Diego, CA, USA) which utilizes
BeadArray technology. Previous cancer SNP technologies using the
BeadArray technology were designed to only detect germline
variations and not optimized for the unique considerations required
for testing cancerous tissues. Platforms designed speciﬁcally for the
detection of somaticmutations such as OncoMap (Sequenom, Inc., SanDiego, CA, USA) have also recently been developed. Our customized
assay, using the Golden Gate BeadArray technology can simulta-
neously analyze 376 previously-identiﬁed somatic mutation mapping
to 109 unique genes in up to 96 tumors (Supplement Table 1). The
assaywas designed to characterize themost common pointmutations
in solid and hematological malignancies. Selection of mutations on the
assay was determined by interrogating published resources [COSMIC
database, release 45 [6]] (see Methods). Priority for inclusion on the
assay was given to mutations with high relative frequency in a broad
spectrum of tumor types and those occurring in genes that compose
critical cancer-related pathways (MAP Kinase, AKT signaling, etc.).
2. Results
2.1. Mutation detection
To evaluate the sensitivity and speciﬁcity of this platform to
accurately detect point mutations, a panel of commercially available
cell lines with published mutations was identiﬁed and assayed
(n=321) (Supplement Tables 2, 3). This included 183 missense and
15 complex mutations (e.g. AANTT) (see Section 4.2). A high
proportion of the missense mutations were re-identiﬁed (177/183;
96.7%), while a lower proportion of complex mutations (11/15; 73%)
were detected. Of the 137 cell lines harboring mutations selected for
inclusion in the assay, 45 contained N1 mutation identiﬁed by
conventional methods (co-occurring mutations). For this subset of
cell lines, the assay successfully re-identiﬁed co-mutations in 41/45
(91%) of the cell lines. For the 6 missense and 4 insertion/deletion
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signal was generally very good (i.e. mutations for these probes were
readily detected in other cell lines), suggesting that the Illumina
genotyping assay may not be the primary source of the observed
discordance. In our review of the data reported in the COSMIC
database, there were numerous instances of the same cell line having
different mutation proﬁles for the same gene. For instance, the
hepatocellular cell line SNU-387 is reported to have a NRAS mutation
(Q61K) from Sanger Centre's Cancer Cell Line Project (http://www.
sanger.ac.uk/genetics/CGP/CellLines), but is also reported as not
mutated in another published report [7]. Potential sources of
variability in published reports for the same cell line might include
incomplete sequencing of genes, evolution of mutations in culture,
inclusion of non-somatic mutations, sample contamination, assay
sensitivity or inadequate data interpretation.
Also identiﬁed by the assay were 35 mutations for genes in cell
lines that were previously annotated as ‘wild type’ by other methods
(Supplement Table 4). For example, there were 9 cell lines identiﬁed
with c-MET mutations in the juxtamembrane domain (T1010I,
R988C) which were previously reported to regulate cell proliferation
in small cell lung cancer [8]. Additionally, the assay discovered 33
unreported mutations in cell lines for which screening had not
previously been completed (Supplement Table 5, Table 1). Included in
this newly identiﬁed set are those with oncogene ‘hotspot’mutations,
such as PIK3CA, c-MET, KRAS as well as several tumor suppressors
(e.g. TP53). A selected set of genes known to be frequently involved
with tumorigenesis and progression (PIK3CA, KRAS, c-MET and TP53,
n=50) was a sequence veriﬁed in cell lines where these were
unreported or discordant with previous ﬁndings. An overwhelming
majority of the mutations discovered by the genotyping assay were
conﬁrmed by sequencing (48/50, 96%). This high rate of concordance
supports the use of this platform for the accurate detection of point
mutations in cancer (Supplement Table 6).
2.2. Dilution titration experiments
One important challenge for diagnostics in a clinical setting is
accurate and sensitive measures for biopsied tissue that contain a
mixture of tumor and non-malignant tissue. For example, the
sensitivity of traditional ‘Sanger’ capillary-based sequencing can be
limited to ~50% tumor tissue [9]. Here we demonstrate the ability of
the platform to detect mutations with even greater proportions of
normal DNA (≤40% tumor). To show this, we performed a dilution–
titration experiment with 10 cell lines which collectively harbor 77
previously validated mutations (Supplement Table 7). Tumor cell line
DNA was diluted with non-tumorigenic breast epithelial cell line
MCF10A DNA, which is wild type for all mutations (1:1, 4:1, 3:2, 2:3
and 1:4 tumor-normal ratios, Supplement Table 8). We observed no
signiﬁcant decrease in mutation detection rates in as low as 40%
tumor tissue (64/72 mutations; 83%); however a drop in the
sensitivity of the assay was seen using 20% tumor tissue (46/72;
60%) (Fig. 1a). The genotype signal intensity progressively decreasesTable 1
Conﬁrmed unreported somatic mutations (n=9) found in cell lines using the custom
genotyping (COSMIC release 48).
Cell line Tumor type Gene Amino acid Nucleotide
OCIAML3 AML MET p.T1010I c.3029CNT
SCLC3 Lung TP53 p.E298* c.892GNT
SKO007 Heme MET p.T1010I c.3029CNT
SKBR3 Breast TP53 p.R175H c.524GNA
SCLC3 Lung PIK3CA p.Q546K c.1636CNA
AN3CA Uterus PRKDC p.R1136H c.3407GNA
JURKAT ALL TP53 p.R196* c.586CNT
NCIH2195 Lung TP53 p.V157F c.469GNT
NCIH1404 Lung TP53 p.R158L c.473GNTwith increasing proportions of wild type DNA, where at a low fraction
of tumor tissue, the ‘signal’ approaches clusters for the wild-type
samples (Fig. 1b).
The false-negatives seen at higher tumor-normal ratios were a
subset of those detected at lower tumor DNA levels (Supplement
Figure 1), indicating that speciﬁc probes may be predictably more
prone to noise than others. For instance, some probes for mutations in
TP53 can exhibit lower signals due to high rate of mutations in
neighboring genomic regions or genomic loss. Expectedly, no false
positives were detected, conﬁrming that the inﬁltrating wild type DNA
was the source of the discordance due to extremely low proportions of
mutant/wild-type alleles in the sample.
2.3. Detection of copy number alterations
Other genotyping platforms have been adapted to measure DNA
copy number alterations [10]. Similarly, the normalized intensity data
from this assay can be used to quantify gene DNA copy number. The
relative intensities of probes mapping to genes commonly ampliﬁed
(e.g. ERBB2, EGFR) or deleted (e.g. RB1, PTEN) demonstrate this
capability. A systematic review of the platform's ability to detect DNA
copy number alteration was done by comparing probe intensities to
those calculated by the Affymetrix 500k SNP platform (http://cabig.
cancer.gov/; n=314 cell lines) (methods described in [11]). The
concordance of six genes known to be ampliﬁed in cancer (EGFR,
ERBB2, KIT, KRAS, c-MET, PIK3CA; Supplement Table 10) and four genes
deleted in cancer (PTEN, RB1, CDKN2A, and STK11; Supplement Table 11)
were analyzed between the two platforms. Overall, we found the
detection of copy number alterations between the platforms had
reasonable concordance for both oncogenes (Fig. 2, Supplement
Table 12) and suppressor genes (Supplement Figure 2, Supplement
Table 12). For instance, the genes in cell lines unambiguously ampliﬁed
(e.g. Affy log2 ratioN1.0, seeMethods), 26/27 (96%)were also ampliﬁed
according to the Illumina platform. One prominent example of
concordant intensities between the two platforms is exhibited by
ERBB2 which is commonly ampliﬁed in breast tumors. Multiple copy
number changes for an individual tumor can also be reviewed in this
manner. For instance, the breast cell line MDA-MB-468 has high signal
intensity for probes mapping to EGFR relative to other cell lines,
indicating a copy number ampliﬁcation at that locus as well as reduced
intensity for probesmapping to RB1 and SMAD4 (Fig. 3). The occurrence
of these DNA copy number alterations in this cell line was conﬁrmed by
previously published analyses [12,13].
For two of the tumor suppressor genes (RB1, STK11) we observed
lower concordance for copy number estimations between the
Illumina and array-based platforms. To determine if probe density
may be a source of the discordance observed, a review of the LOH and
copy number cell line studies that use the high-density Affymetrix
SNP 6.0 platform [14] (Cancer Genome Project at the Sanger Institute;
http://www.sanger.ac.uk/genetics/CGP/CellLines/). These studies
show a greater concordance with copy number variance (CNV)
observations from the customized assay (Supplement Table 13). For
instance, STK11 is lost on the Illumina and SNP 6.0 platform; however
this loss is not detected on the 500k Affymetrix platform. The low
probe density of the 500 K platform for STK11 may explain this
discordance. The Illumina and SNP 6.0 have 7 and 6 probes
respectively.
3. Discussion
The ability to simultaneously detect numerous point mutations
with DNA copy number alterations for major cancer causing genes can
greatly improve the ability to tailor therapy for patients that are most
likely to respond, and can suggest alternative treatments or new
strategies for drug combinations. This high throughput genotyping
technology offers a robust, scalable and cost effective way (at a few
Fig. 1. Tumor dilution titration using non-tumorigenic MCF10A. (a) Percentage of known mutations (n=77) detected in the dilution titration experiment (x axis — ratio of tumor:
normal). (b) Detection of PIK3CA E545Kmutations in titrated proportions for the HCT-15 cell line where 20% tumor is still detectable and clusters separately fromwild-type samples.
Fig. 2. Concordance of relative intensities in cell lines for both the Illumina Golden Gate(x-axis) and Affymetrix 500k platform (y-axis) among 6 major oncogenes (EGFR, ERBB2, KIT,
KRAS, MET, PIK3CA). Higher intensity values represent copy number gains.
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Fig. 3. The relative intensities for individual genes for a tumor cell line indicate copy
number changes. For the breast cell line MDA-MB-468, copy number ampliﬁcations in
EGFR are present while RB1 and SMAD4 locus is lost, consistent with previous studies.
299C. Moy et al. / Genomics 98 (2011) 296–301hundred dollars per sample) to screen a large number of tumor
samples for potential predictors of patient response to treatment
modalities.
One of the major challenges with detection of somatic mutations
in tumor samples is the limited availability and heterogeneity of the
sample DNA. This tumor/normal DNA titration study suggests that
signal demarcation andmutation detection can be optimized for those
mutations with lower quality probes (e.g. PIK3CA E545K) through the
use of a carefully designed set of tumor-normal positive controls.
Detection can be achieved with 20% tumor; the rate may be improved
using a solution based assay (Veracode) for the Golden Gate in lieu of
the BeadArray due to the larger number of alleles per bead. However,
this would come at a tradeoff of a lower throughput per assay (e.g. 48
plex).
Unlike the previous generation of multiplex genotyping technol-
ogies that have been employed for analyzing somatic mutations [15],
this adaptation, which uniquely applies the Illumina platform, can be
used either ‘out of the box’ or easily tailored for a speciﬁc screening
strategy. This adaptation can also be uniquely applied to detection of
copy number alterations for major oncogenes, reducing the need to
run costly parallel assays for the same sample.
While next generation sequencing technologies still remain expen-
sive for larger studies and require signiﬁcant amounts of input DNA, a
carefully constructed genotyping assay can serve as a powerful and
efﬁcient technology for translational applications such as biomarker
discovery. With this platform's demonstrated high sensitivity to detect
important somatic mutations, ability to tolerate the inﬁltrating normal
tissue and capacity to quantify DNA copy number alterations, all from
minimal DNA input at relatively low cost, make this an attractive assay
for exploratory analysis of mutations in cancer.
4. Materials and methods
4.1. Cell culture and DNA isolation
Cell lines were thawed and grown in RPMI 1640 media (Invitrogen,
72400) supplemented with 10% fetal bovine serum (Hyclone,
SH30071.03), 1 mM sodium pyruvate (Invitrogen, 11360), and 2 mM
Glutamax (Invitrogen, 35050) for several passages before being frozen
down as stocks. Once cells reached a density suitable for freezing, they
were trypsinized using TrypLE (Invitrogen, 12563) and resuspended incomplete media for counting. Cells were then centrifuged at 1000 rpm
for 10 min and the supernatant was aspirated. The remaining cell pellet
was resuspended in freezing media (90% FBS, 10% DMSO) to give a
concentration of cells between 2 million and 5 million cells per ml.
These cells were frozen and stored at −140 °C. These cells were
subsequently thawed, rinsed with 10 ml of D-PBS, centrifuged and
resuspended in 200 μl of D-PBS for use with the DNA isolation kit. DNA
was isolated and puriﬁed using Qiagen QIAmp® according to the
manufacturer's protocol. Samples were titrated to 50 ng/μl of DNA and
250 ng of total DNA (5 μl) were used for the assay. Subsequent dilutions
of were carried out to reach 80%, 60%, 40% and 20% of normal for the
dilution titration experiments.
4.2. Selection of mutations and assay design
Prior to the custom probe construction by Illumina, all probes
sequences are sent to Illumina for evaluation using the Illumina Assay
Design Tool (ADT). Each probe is given a score based on a number of
criteria important for a functional assay. Those probes that have an
adequate score (0.4 or greater) were considered sufﬁcient for the probe
to be included on the assay. Complexmutations (‘indels’)were carefully
designed and those complex mutations that could be represented as a
SNP somewhere on the mutant allele were considered candidates for
the platform.
Selections of mutations for the assay were prioritized by those
mutations most frequently present in a broad spectrum of tumor types
(e.g. KRAS G12D). COSMIC and other published sequencing effortswere
reviewed to generate a database of candidate mutations for the assay.
Greater priority was given to genes with oncogenic activity (PIK3CA,
RAS) versus genes with suppressor function (p53, RB1). Prioritizing
oncogenic mutations over suppressor mutations enables a greater
proportion of a gene's mutation proﬁle to be evaluated, providing for
better utilization of the space available on the assay. However, targeting
oncogeneswith a PCR based genotyping assay can present challenges in
hotspot regions, since probes in these regions may interfere with each
other, adversely affecting the overall performance of the assay. To
resolve this, probes for hotspot regions were allocated into separate
‘pools’ for each batch (A, B, C, D) and run in a separate experiment.
4.3. Illumina Golden Gate genotyping
4.3.1. Illumina workﬂow
The Illumina Golden Gate workﬂow generates SNP speciﬁc PCR
products that are subsequently hybridized to beads either on a solid
matrix (the Bead Array platform). Three oligonucleotides are synthe-
sized for each SNP: two allele speciﬁc oligos (ASOs) that distinguish the
SNP, and a locus speciﬁc sequence (LSO) just downstream of the SNP.
The ASO and LSO sequences also contain target sequences for a set of
universal primers while each LSO also contains a particular address
sequences (the “Illumicode”) complementary to sequences attached to
beads.
All the oligonucleotides querying a set of SNPs are synthesized and
pooled by Illumina. To carry out the assay, this pooled oligo set (the
“OPA”) is hybridized simultaneously to genomic DNA representing a
single sample/reactionwell. Following allele speciﬁc primer extension
and ligation reactions, a set of ﬂuorescently labeled universal primers
(Cy3 and Cy5 labeled P1 and P2, respectively) is added and PCR is
carried out, generating multiple labeled amplicons representing
hundreds of different SNPs. These ﬂuorescent products are then
combined with Illumina beads on the Sentrix Array Matrix. The
address sequencewithin the PCR amplicons hybridize to their cognate
sequence on the bead, and the ﬂuorescence on each bead is quantiﬁed
resulting in a signal associated with a particular address sequence.
Each address translates to a particular locus, and the presence of Cy3,
Cy5, or both signals on a given bead type indicates AA, BB, or AB
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Studio software.
4.3.2. Sample and probe QC/ﬁltering
Samples are clustered based on the zygosity of the loci being
interrogated. The “Call Rate”measure is a quality scoringmetric that is
used by the Genome Studio software. Samples that were below 0.90
for the Call Rate were excluded from analysis and subsequently re-
clustered until all Call rates for remaining samples were greater than
0.90. Probes are given a GenTrain Score between 0 and 1. As a
guideline, GenTrain scores of below 0.5 were typically excluded from
most analyses. Greater emphasis on the qualitative assessment of the
clustering was used for ascertaining probe quality for each assay,
rather than relying exclusively on GenTrain Scores. The signal
intensities (NORM R) for all probes were collected and transformed
(log 2) to evaluate copy number variation.
4.4. Data analysis
4.4.1. Mutation detection
GoldenGate Genotyping Assay data generated using the BeadArray
Reader GenomeStudio Genotyping Module. Primary data analyses,
such as raw data normalization, clustering, and genotype calling are
performed using algorithms in the GT Module. Data quality is con-
ﬁrmed with internal controls and other QC functions. Individual SNPs
can be viewed as GenoPlots and edited if necessary. The graphical
display of results in GenomeStudio GTModule is a GenoPlot, with data
points color coded for the call (red = AA, purple = AB, blue = BB).
Genotypes are called for each sample (dots) by their signal intensity
(Norm R, y-axis) and Allele Frequency (Norm Theta, x-axis) relative to
canonical cluster positions (dark shading) for a given SNP marker.
Each candidate mutation is reviewed by an analyst to make a ﬁnal call
on the mutation status for each cell line and corresponding genotype.
To ensure the highest sensitivity among the most important somatic
variants (e.g. V600E) diluted cell lines can be used as controls for
signal detection.
4.4.2. Mutation validation set
Generation of the validation set (Supplement Table 3) of expected
mutation calls required the collection of mutation data from previous
published reports (COSMIC, release 48). These data were collected and
compared to thosemutations included on the assay. There are a number
of cell lines in the validation set that have different cell line names with
high levels of shared genetic identity. This may be due to historical
contamination or the cell line is derived from the same patient at
different timepoints. The Cell Line Identity Typing resource at Sanger is
a useful guide to see which cell lines fall into this category and can
be viewed at http://www.sanger.ac.uk/genetics/CGP/Genotyping/
synlinestable.shtml. Those mutations that had an equal number of
conﬂicting genotype calls (e.g. Both ‘WT’ and mutant) were considered
ambiguous and excluded from analysis.
4.4.3. Surrogate mutation calls
Included in the validation set for reference were mutations that
were detected by the Illumina genotyping platform that did not have
exact matches for mutation but were at the same loci, thus generating
a ‘detectable signal’ (e.g. KRAS_c.35GNA probe can detect
KRAS_c.35GNT). This can be beneﬁcial for detection lower frequency
mutations in hotspot regions.
4.4.4. Copy number data generation for Illumina Golden Gate
The original signal intensities provide by the Genome Studio
software (Normalized R values) were collected and the average
intensity of each probe for all cell lines was calculated. The average
intensity was then subtracted from the original signal intensity value.
A constant of 2 was added to these values to perform logarithmtransformation. The log2 value of the relative signal intensity was
generated for every probe and cell line on the assay (Supplement
Table 9). These relative intensity signals were imported into Spotﬁre
DXP software for visualization (Fig. 1) and analysis. Relative intensity
values less than 0.8 and was considered a loss in the region while
relative intensities greater than 1.15 were considered a gain.
4.4.5. Copy number data generation for Affymetrix 500k SNP platform
DNA copy number data was collected for all cancer cell lines using
the Affymetrix 500 K chip (Affymetrix Inc, Sunnyvale, CA). First, DNA
was extracted fromeach line usingGenEluteMammalianGenomic DNA
miniprep kit (Sigma, St. Louis, MO). Two aliquots (250 ng each) were
digested with the restriction enzyme Nsp or Sty (New England Biolabs,
Boston, MA). Digested DNAwas subsequently ligated to an adaptor and
ampliﬁed by PCR using Platinum Pfx DNA Polymerase (Invitrogen),
yielding a product of approximately 250–2000 bp. For each enzyme
digest, PCR was carried out in four 100 μl aliquots, pooled, puriﬁed,
quantiﬁed, normalized to 40 μg/45 μl and fragmented with DNase I to
yield a size rangeof approximately 25–200 bp. The fragmentedproducts
of the cancer cell lines were then labeled, denatured, and hybridized to
theAffymetrix 500 K chip.Upon completionof hybridization, each assay
was washed and stained using Affymetrix ﬂuidics stations. Image data
were acquired using the GeneChip Scanner 3000 (Expression Analyisis,
Inc, Durham NC). Similarly collected data from a panel 10 non-
tumorigenic lymphoblastic cell lines were used to calculate DNA copy
number.
DNA copy number for each locus was calculated using the following
procedures:
1. All ‘SNP Chip’ images (‘CEL ﬁles’), were extracted using the
Affymetrix Genotype software, and read and normalized using
the dChip software package (Lin et al. 2004). SNP-wise ‘copy-
number ratios’ (log2 scale) were calculated for all cancer cell lines
by dividing the SNP intensity score by the respective median
intensity score for the lymphoblastic reference panel. Data were
adjusted under the assumption that the median copy number for
all samples was diploid.
2. Finally, copy number inferences were made by circular binary
segmentation (CBS) to reduce noise (e.g. from unmasked complex
sequences in the target) and provide a consensus score for all
regions of the genome based on at least two underlying SNP
(Olshen et al. 2004).
3. Log2 ratio cutoffs based upon previous comparisons of this platform
to karyotype data (Greshock et al. 2007) were used to classify genes
as having copy number gains of 3–5 copies (0.25–0.65), gains N5
copies (N0.65), monsomies (−0.25–0.75) or homozygous losses
(b−0.75).
4.4.6. Cancer Genome Project LOH and copy number
To ascertain the most accurate copy number values for the
discordant values, cell line copy number studies using the Affymetrix
SNP 6.0 platform from Sanger Institute (http://www.sanger.ac.uk/cgi-
bin/genetics/CGP/cghviewer/CghHome.cgi) were reviewed. Since
these studies use a platform with much higher probe densities,
including a large panel of structural variation copy number probes, it
is an excellent standard to examine the discordant CNV values
observed. A total of 27 copy numbers were considered to have
discordant CNV values and were compared to the CNV data from the
Affymetrix 6.0 platform at the Sanger Institute (Supplement Table 13).
Overall, we found the Illumina platform was a better predictor of CNV
compared to the Affymetrix 500k for the selected genes.
4.4.7. Sanger based sequencing
All primers were synthesized by Integrated DNA Technologies
Coralville, IA. PCR was performed in 50 μl reactions. The Master Mix
consists of; 121.5 μl PCR water, 25 μl 10 mM dNTP mix, 25 μl 10× PCR
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each Forward/Reverse primers. 40 μl of this master mix is used for each
reaction. 10 μl of DNA (1.5 ng/μl) is added to the reaction. Reactions
were carried out in an ABI 9700 thermocycler (Applied Biosystems, CA)
using a touchdown PCR protocol (1 cycle of 96 °C for 2 min; 3 cycles of
96 °C for 10 s, 64 °C for10 s, 70 °C for 30 s;3 cycles of 96 °C for 10 s, 61 °C
for 10 s, 70 °C for 30 s; 3 cycles of 96 °C for 10 s, 58 °C for 10 s, 70 °C for
30 s; 40 cycles of 96 °C for 10 s, 57 °C for 10 s, 70 °C for 30 s). Templates
were puriﬁed using AMPure (Beckman Coulter Genomics, MA)
and sequencing carried out with Big Dye Terminator Kit (Applied
Biosystems, Foster City CA). Dye terminators were removed using
ethanol precipitation and sequence reactions were obtained on an ABI
PRISIM 3730xl. Sequence traces were compared to genomic reference
sequences for each gene and differences detected using the Mutation
Surveyor software (Softgenetics, State College, PA).
4.4.8. Cell line identity testing
Genotype calls from the 500k SNP chip were mad using the
Affymetrix BRLMM algorithm. Genetic backgrounds for each cell line
were compared to the identities of entire cell line panel. Those cell lines
with different names but identities greater than 90% are identiﬁed
[Supplement Table 14].
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.ygeno.2011.04.008.
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